P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

• M. Wang,
• M. Mei,
• P. M. Barr,
• J. Barrientos,
• S. de Vos,
• R. Furman,
• K. Patel,
• P. A. Thompson,
• M. Choi,
• A. Kallam,
• Y. Zhu,
• S. Chakraborty,
• P. Marinello,
• S. E. Spurgeon

Affiliations

M. Wang

1 MD Anderson Cancer Center, Houston

M. Mei

2 City of Hope Cancer Center, Duarte

P. M. Barr

3 University of Rochester Medical Center, Rochester

J. Barrientos

4 Northwell Health, Inc., New Hyde Park

S. de Vos

5 UCLA Santa Monica Medical Center, Santa Monica

R. Furman

6 Weill Cornell Medical College, New York

K. Patel

7 Swedish Cancer Institute, Seattle

P. A. Thompson

1 MD Anderson Cancer Center, Houston

M. Choi

8 University of California San Diego, San Diego

A. Kallam

9 University of Nebraska Medical Center, Omaha

Y. Zhu

10 Merck & Co., Inc., Kenilworth

S. Chakraborty

10 Merck & Co., Inc., Kenilworth

P. Marinello

10 Merck & Co., Inc., Kenilworth

S. E. Spurgeon

11 Oregon Health and Science University, Portland, United States of America